Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | MTOR | P42345 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.37 |
| ▸ | ALB | P02768 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.37 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | POLA1 | P09884 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15239320 | 0.91 | LMNA (0.47) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL3272285 | 0.90 | LMNA (0.51) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL28645147 | 0.89 | LMNA (0.46) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL31070840 | 0.88 | LMNA (0.49) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL2180644 | 0.88 | LMNA (0.49) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL6060585 | 0.88 | LMNA (0.45) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL7196048 | 0.87 | LMNA (0.46) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL7775032 | 0.87 | LMNA (0.48) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL25407209 | 0.87 | LMNA (0.44) | LMNAMTORTHRBMDM2NCOA1 | |
| Phosphoric Acid SCHEMBL16655013 | 0.86 | LMNA (0.47) | LMNAMTORTHRBMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114533739-A | Application of nucleoside analogue in preparing medicine for preventing or treating gastrointestinal tract diseases | 兰州大学 | 2022-05-27 | — | — | CN | claimed |
| EP-4519436-A1 | LOCALIZATION OF TRANS-SPLICING NUCLEIC ACID MOLECULES TO AND WITHIN THE CELLULAR NUCLEUS | Tacit Therapeutics, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20250074895-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | BLUEPRINT MEDICINES CORPORATION | 2025-03-06 | — | — | US | disclosed |
| EP-4423271-A2 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR KNOCKING OUT C5 | Regeneron Pharmaceuticals, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-4423119-A1 | COMPOSITIONS AND METHODS FOR EXPRESSING FACTOR IX FOR HEMOPHILIA B THERAPY | Regeneron Pharmaceuticals, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2024133884-A2 | OPTIMIZED TAILING OF MESSENGER RNA | SANOFI (FR) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024102677-A1 | CIRCULAR RNA COMPOSITIONS | ORNA THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024054867-A1 | MODIFIED MOLECULAR BEACONS FOR IMPROVED DETECTION SPECIFICITY | BECTON, DICKINSON AND COMPANY (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2023215761-A1 | LOCALIZATION OF TRANS-SPLICING NUCLEIC ACID MOLECULES TO AND WITHIN THE CELLULAR NUCLEUS | TACIT THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023115221-A1 | IONIZABLE DILSULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2023-06-29 | — | — | WO | disclosed |
| EP-2321332-B1 | SELF-AVOIDING MOLECULAR RECOGNITION SYSTEMS IN DNA AMPLIFICATION | BENNER STEVEN A (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20120190688-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BRUNCKO MILAN (US) | 2012-07-26 | — | — | US | disclosed |
| US-20110263599-A1 | 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES | 2011-10-27 | — | — | US | disclosed |
| EP-2321332-A1 | SELF-AVOIDING MOLECULAR RECOGNITION SYSTEMS IN DNA AMPLIFICATION | Benner, Steven A. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20100305118-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2010021702-A9 | SELF-AVOIDING MOLECULAR RECOGNITION SYSTEMS IN DNA AMPLIFICATION | BENNER STEVEN ALBERT (US) | 2010-05-06 | — | — | WO | disclosed |
| US-20100099738-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-04-22 | — | — | US | disclosed |
| WO-2010021702-A1 | SELF-AVOIDING MOLECULAR RECOGNITION SYSTEMS IN DNA AMPLIFICATION | BENNER STEVEN ALBERT (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20030083281-A1 | Antisense modulation of PKA regulatory subunit RII beta expression | ISIS PHARMACEUTICALS INC. | 2003-05-01 | — | — | US | disclosed |
| US-20030060437-A1 | Antisense modulation of dual specific phosphatase 5 expression | ISIS PHARMACEUTICALS INC. | 2003-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099738-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | LIPA, LIPG, LIPC | LMNA 1949/4885MTOR 4369/4885THRB 1606/4885 |
| US-20250074895-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | CDK2, CDK20, CDK2AP1 | LMNA 1732/4885MTOR 312/4885THRB 3235/4885 |
| US-20100305118-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | IGF1R, TK1, CDK2 | LMNA 1836/4885MTOR 192/4885THRB 418/4885 |
| US-20120190688-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | LMNA 2607/4885MTOR 1387/4885THRB 2265/4885 |
| US-20110263599-A1 | 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, API5 | LMNA 1545/4885MTOR 1956/4885THRB 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.